HCPLive
@HCPLiveNews
Followers
8K
Following
5K
Media
14K
Statuses
58K
Everything you need to enhance your clinical approach to improving patient care.
United States
Joined January 2009
2025 is coming to a close. We're celebrating with our 9th annual #ThisYearInMedicine series. Throughout December, we'll be spotlighting the trends, stories, and data that defined specialty care this past year Check back on this thread throughout the month for installments!
1
0
2
ICYMI: A new episode of the #SkinofColorSavvy podcast is out now!🎙️ Watch this discussion with @drcoreyhartman (of @SkinWellDerm) on notable takeaways from the recent @SkinOfColor Virtual Media Day event.🌟 🔗View the full video/summary here: https://t.co/STG1nxBnBn
0
0
0
New survey data show many obstetric physicians rarely refer pregnant patients to allergists despite #allergy, asthma, and drug reactions affecting maternal and fetal health.🔍 Read more about barriers: https://t.co/TjuvQy2NnM
#ACAAI2025
0
0
0
Are you caught up on the latest in #dermatology news from November? If not, don't worry! We have released a new Month in Review of 8 recent headlines, highlighting new data, news coverage, & interviews with experts in the field of skin health. View here: https://t.co/igXXO3X0fe
0
0
0
A new episode of the #SkinofColorSavvy podcast is out now!🎙️ Check out this discussion with @drcoreyhartman (of @SkinWellDerm) discussing notable takeaways from the recent @SkinOfColor Virtual Media Day event.🌟 🔗View his discussion here: https://t.co/P4OPFiRt3B
0
0
0
In this recent Peer Exchange series, doctors @MKIttlesonMD, @Ron_Witteles, @MarthaGrogan1, and @CesiaGallegos explore early detection, diagnosis, and treatment of ATTR-CM, plus TTR stabilizers, gene-silencing therapies, and emerging data. Watch Now: https://t.co/q2oEax3RUb
0
3
8
What's new in hereditary angioedema? Learn how 3 FDA approvals from June-August 2025 have set the stage for a new era of management for the rare disorder. https://t.co/eDnQC0mP52
0
0
0
In 2025, the FDA approved 3 new therapies in just 3 months for HAE. This marks a significant shift for clinicians and families with the rare disorder. The third installment of our #ThisYearInMedicine series captures perspective from the frontlines: https://t.co/3n56DejoRw
0
2
2
Ghaith Noaiseh, MD, Teja Kapoor, MD, Thomas Grader-Beck, MD, and Nehad Soloman, MD, FACR, explore diagnostic and management challenges in Sjogren’s Disease, evaluate emerging therapies, and share considerations for integrating novel treatments. Watch Now: https://t.co/ao3z1KQA86
0
1
1
In this Special Report, learn about the evolving CSU treatment landscape with Jason Hawkes, MD, MS, and explore how remibrutinib, the first oral BTK inhibitor, is reshaping care with rapid, sustained efficacy and a strong safety profile. Watch Now: https://t.co/EXC1edn8fJ.
0
0
0
ICYMI: New research is shedding light on state- and local-level geographic disparities in the availability of gastroenterologist care, highlighting limited access to care in rural areas and areas with low household incomes relative to urban areas. 🔗View:
hcplive.com
State- and local-level disparities in the availability of gastroenterologist care disproportionately affect patients with IBD and populations living in rural and high-poverty areas.
0
0
0
#Hepatology has undergone meaningful change this year, with MASH/MASLD therapies, HBV updates, & advances in diagnostics redefining the approach to chronic #liver disease. Our #ThisYearInMedicine feature breaks down the developments shaping the field: https://t.co/8Ex08sOfPJ
hcplive.com
Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.
1
0
0
We spoke with C. Michael Gibson, MD, CEO of the Baim and PERFUSE research centers at Harvard Medical School, to discuss the promising new data from COLLIGO-HCM, which saw zalunfiban improve STEMI outcomes prior to arriving at the hospital. Watch now: https://t.co/GbE0q2xTl4
0
0
2
Pulmonary rehabilitation significantly reduced FeNO levels in #asthma patients with high baseline FeNO, indicating its potential as a complementary asthma management strategy. Read more:
hcplive.com
PR was seen to reduce FeNO, a biomarker of type 2 inflammation, in a new study.
0
1
2
November Nephrology Month in Review: Immune-targeted IgAN advances, new FDA moves in rare kidney disease, and key transplant updates. Full recap:
hcplive.com
Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.
0
0
2
Trait-based, personalized approaches to asthma and COPD are redefining pulmonary care and pushing the field closer to precision care. Explore the full story in our #ThisYearInMedicine feature: https://t.co/8Ex08sOfPJ
#Pulmonology
hcplive.com
Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.
1
0
0
2025 has been a watershed moment for #hepatology, with long-awaited breakthroughs and advancess reshaping how clinicians manage chronic #liver disease. We asked 7 leading experts to discuss top developments for our #ThisYearInMedicine series: https://t.co/KiPHXdF6QZ
0
2
2
ICYMI: @BiofronteraInc announced the submission of a supplemental New Drug Application (sNDA) to the #FDA for Ameluz-PDT (photodynamic therapy) as a treatment for superficial basal cell carcinoma.🔍 🔗View more here: https://t.co/iMSxvm3bq4
#dermatology #SkinCancer
0
0
0
NEW: @BiofronteraInc announced the submission of a supplemental New Drug Application (sNDA) to the #FDA for Ameluz-PDT (photodynamic therapy) as a treatment for superficial basal cell carcinoma.🔍 🔗View more here: https://t.co/iMSxvm3bq4
#dermatology #BCC #SBCC #SkinCancer
0
1
0